清普生物科技

ClearPoint Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development of innovative pain management solutions. The company leverages its proprietary Clear-S and Clear-L drug delivery platforms to develop non-opioid analgesics that offer improved safety and efficacy profiles. Its lead product candidate, QP001, is a long-acting injectable ketorolac tromethamine currently in Phase 3 clinical trials for postoperative pain. Another key program, QP002, is a long-acting local anesthetic designed to provide extended pain relief after surgery. ClearPoint Biotech aims to address significant unmet medical needs in the global analgesic market, particularly by providing alternatives to opioid-based treatments. The company's research and development efforts are focused on transforming existing drugs into superior formulations with optimized pharmacokinetic properties.